U.S., April 17 -- ClinicalTrials.gov registry received information related to the study (NCT06930755) titled 'Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer' on April 09.
Brief Summary: This is a multicenter, open-label Phase Ia/b study on the safety and efficacy of the combination of NMS-03305293 and topotecan in patients with recurrent ovarian cancer, with dose-limiting toxicity (DLT) escalation. The aim of this study is to determine the safety and tolerability, as well as to evaluate the anti-tumor efficacy and pharmacokinetics of NMS-03305293 in combination with topotecan.
Study Start Date: June 28
Study Type: INTERVENTIONAL
Condition:
Ovarian Cancer
Intervention:
DRUG: NMS-03305293
Route of administration:...